| Expression pattern: |
UP |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
CircHAS2 is upregulated in serum of GC patients, can distinguish GC and early GC patients from controls, differentiates GC from gastritis, correlates with malignancy-related clinicopathological features, and may monitor postoperative and chemotherapy-related prognosis. |
| Molecular mechanism: |
CircHAS2 can be secreted from cells into the blood; this study mainly evaluated its serum biomarker performance and did not experimentally define a regulatory molecular mechanism. |
| Biological pathway or process: |
not specified |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Sanger Sequencing; Clinical Sample Validation; ROC Analysis; Cohort Study; Survival Analysis |
| Clinical significance: |
CircHAS2 can be used as an effective diagnostic and prognostic serum biomarker for GC; it identifies GC and early GC, differentiates GC from gastritis, correlates with differentiation, TNM stage, histological type and lymph node metastasis, decreases after surgery and normalizes after second-stage chemotherapy, and low expression is associated with better OS and PFS. |
| Description: |
This study identifies serum circHAS2 as an upregulated circRNA biomarker in gastric cancer. Its serum expression distinguishes GC and early GC from controls, correlates with malignancy-related clinicopathological parameters, decreases after surgery and chemotherapy, and high expression is associated with worse survival. |
| Confidence score: |
0.5918 |